MOMENTA PHARMACEUTICALS, INC. Inactive Instrument
Momenta Pharmaceuticals, Inc.
Equities
MNTA
US60877T1007
Biotechnology & Medical Research
Presenter SpeechCraig Wheeler (Executives)Good morning, everybody, and welcome to our R&D Day ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.67% | 21.97B | |
| -4.59% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
